Abstract 567P
Background
Leptomeningeal metastasis (LM) is one of the most severe complications of non-small cell lung cancer (NSCLC) and is always accompanied by poor prognosis. The optimal treatment for EGFR–mutated NSCLC patients with LM after EGFR-TKI therapy failure remains unclear. Furmonertinib is a novel third-generation EGFR-TKI. A phase I-II dose-expansion study (NCT03127449) suggested that furmonertinib had a favorable antitumor activity with a wide therapeutic range and minimal toxicity. This retrospective study aimed to evaluate the efficacy and safety of furmonertinib 160mg in combination with bevacizumab and intrathecal chemotherapy in EGFR-mutated NSCLC patients with LM after initial TKI failure in the real world.
Methods
We retrospectively studied 19 NSCLC pts with LM treated with furmonertinib in combination with bevacizumab and intrathecal chemotherapy between February 2021 and April 2023 at Nanjing Chest Hospital. All of them received third-generation EGFR TKIs-based therapies previously. Objective response rate (ORR), disease control rate (DCR), progression free survival (PFS), and toxicity were assessed.
Results
The median age was 57 years (range: 31-77), 6 (31.6%) were males and 13 (68.4%) were females. 4 (21.1%) had EOCG 2, 7 (36.8%) had ECOG 3, and 8 (42.1%) had ECOG 4. 16 patients (84.2%) had partial remission (PR) of LM lesions, 3 patients (15.8%) had stable disease (SD). The intracranial ORR (iORR) was 84.2% and intracranial DCR (iDCR) was 100%. 5 patients achieved PR and 14 patients had SD in the whole lesion, ORR was 26.3% and DCR was 100%. Median PFS was 11.9 months (95% CI 2.8–21.0). The overall survival data were not mature (the overall maturity was 26%). Treatment-related adverse events of ≥ grade 3 occurred in only 1 (5.3%) of 19 patients. Safety profile consistent with previous studies of furmonertinib.
Conclusions
Rechallenges of furmonertinib in combination with bevacizumab and intrathecal chemotherapy has shown significant efficacy and tolerable safety profile in EGFR–mutated NSCLC patients with LM after third-generation EGFR-TKIs treatment failure. The further exploration is ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract